Skip to content

52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study.

Oct 2026 · Journal of American Academy of Dermatology · 0 citations
Medicine

TL;DR

Ruxolitinib cream applied as needed over 44 weeks was well tolerated and demonstrated disease control in children aged 2-11 years, consistent with findings in adolescents and adults.

Abstract

Background

Ruxolitinib (selective Janus kinase [JAK]1/JAK2 inhibitor) cream demonstrated efficacy and safety vs vehicle during 8 weeks of continuous use in a phase 3 study of children with atopic dermatitis (AD).

Objective

To evaluate long-term safety (LTS) and disease control with as-needed ruxolitinib cream use in children.

Methods

Children aged 2-11 years with mild-to-moderate AD initially randomized to ruxolitinib cream (0.75% or 1.5%) in the 8-week study continued the same twice-daily (BID) regimen for an additional 44 weeks but only applied cream as needed BID; patients initially on vehicle were rerandomized (1:1) to apply either ruxolitinib cream strength as needed. Safety and disease control were assessed.

Results

No new safety signals emerged among children who applied ruxolitinib cream in the LTS period (N=282). Application site reactions were infrequent (1.1%), and no serious treatment-related adverse events were observed. Among patients initially randomized to ruxolitinib cream (0.75%/1.5%), disease control was maintained to Week 52 (Investigator's Global Assessment score 0/1, 79.5%/72.3%; affected body surface area, 2.0%/1.9%).

Limitations

No vehicle control in LTS period.

Conclusion

Ruxolitinib cream applied as needed over 44 weeks was well tolerated and demonstrated disease control in children aged 2-11 years, consistent with findings in adolescents and adults.

View source

Similar papers

Open access Nov 2026

Long-Term Safety of Baricitinib in Pediatric Patients With Atopic Dermatitis Aged 2 to <18 Years With Up to 5.2 Years of Exposure

Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease that frequently begins in childhood and can significantly impact quality of life. Baricitinib, an oral selective Janus kinase inhibitor, has demonstrated efficacy and an acceptable safety profile in pediatric patients with moderate-to-severe AD...

A. Wollenberg, A. Torrelo, Masanori Ikeda et al. · 0 citations
Open access Nov 2026

Study Design for an Open-Label, Efficacy-Assessor-Blinded, Phase 3 Study (START UP) to Compare the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Introduction & Objectives While phase 3 studies established the safety and efficacy of upadacitinib (UPA), an oral JAK inhibitor, for treatment of atopic dermatitis (AD) in adults and adolescents,1-3 it is important to evaluate its safety, efficacy, and optimal dosing in the younger pediatric population. START UP is an...

A. Paller, V. Prajapati, Ulrike Blume-Peytavi et al. · 0 citations
Open access Oct 2026

Cumulative Disease Control with Upadacitinib in Moderate-to-Severe Atopic Dermatitis-A 52-Week Multicenter Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis).

INTRODUCTION Fixed-timepoint endpoints may not fully capture longitudinal treatment benefit in atopic dermatitis (AD). We evaluated the 52-week real-world effectiveness and safety of upadacitinib, focusing on cumulative disease control. METHODS This multicenter retrospective analysis of prospectively collected LANDSC...

L. Potestio, M. Bianco, L. Mastorino et al. · 0 citations
Open access Nov 2026

Ruxolitinib Cream Improves Clinical Outcomes in Moderate-to-Severe Non-Atopic Chronic Hand Eczema: Responses by Subtype

Chronic hand eczema (CHE) is characterized by persistent or recurrent inflammatory lesions on the hands and wrists. Ruxolitinib (Janus kinase [JAK]1/JAK2 inhibitor) cream has demonstrated efficacy in atopic and nonatopic hand eczema. In a phase 2 study in adults with moderate-to-severe nonatopic CHE (NCT05906628), 1.5%...

M. Zirwas, R. Chovatiya, Benjamin D. Ehst et al. · 0 citations
Open access Oct 2026

Long-Term Disease Control During Continuous Treatment with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: a Real-World Monocentric Retrospective Study

Real-world evidence on long-term effectiveness and safety of oral Janus kinase (JAK) inhibitors in atopic dermatitis (AD) remains limited. This study evaluated sustained long-term clinical and patient-reported disease control and safety during continuous treatment with upadacitinib 30 mg or baricitinib 4 mg. This monoc...

F. D'Oria, Costanza Falcidia, Giulio Foggi et al. · 0 citations
Open access Oct 2026

Vitiligo Biomarker CXCL10 Correlates With Clinical Response to Ruxolitinib Cream in the Phase 2 Randomized TRuE-V Mechanism-of-Action Study.

Data confirm a role for the IFN-γ-CXCL10 axis in vitiligo pathogenesis and suggest that reductions in CXCL10 expression correlate with clinical repigmentation with ruxolitinib cream.

T. Passeron, M. Lebwohl, C. Lynde et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.